Leerink Swann Comments on Heron Therapeutics Inc’s FY2020 Earnings (HRTX)

Heron Therapeutics Inc (NASDAQ:HRTX) – Equities researchers at Leerink Swann upped their FY2020 earnings estimates for shares of Heron Therapeutics in a research note issued on Thursday, Zacks Investment Research reports. Leerink Swann analyst A. Fadia now expects that the biotechnology company will post earnings of $2.12 per share for the year, up from their previous estimate of $1.93. Leerink Swann has a “Outperform” rating and a $22.00 price objective on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ FY2021 earnings at $4.26 EPS and FY2022 earnings at $4.69 EPS.

Several other research analysts have also weighed in on HRTX. Cantor Fitzgerald set a $31.00 target price on Heron Therapeutics and gave the stock a “buy” rating in a report on Friday, October 20th. Oppenheimer started coverage on Heron Therapeutics in a research note on Monday, October 30th. They issued a “buy” rating and a $27.00 price target on the stock. Cowen reissued a “buy” rating and issued a $40.00 price target on shares of Heron Therapeutics in a research note on Monday, November 6th. Mizuho reissued a “buy” rating and issued a $28.00 price target on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Finally, Zacks Investment Research raised Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 8th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $28.82.

Heron Therapeutics (HRTX) traded up $0.80 during mid-day trading on Monday, reaching $23.20. The company’s stock had a trading volume of 818,100 shares, compared to its average volume of 980,866. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $1,447.04, a price-to-earnings ratio of -6.12 and a beta of 1.87. Heron Therapeutics has a 52-week low of $12.70 and a 52-week high of $24.80.

In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of Heron Therapeutics stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the sale, the vice president now owns 7,584 shares of the company’s stock, valued at approximately $151,680. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 19.93% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its position in shares of Heron Therapeutics by 2.2% in the third quarter. Janus Henderson Group PLC now owns 5,767,495 shares of the biotechnology company’s stock valued at $93,145,000 after acquiring an additional 126,039 shares during the last quarter. BlackRock Inc. increased its position in shares of Heron Therapeutics by 3.2% in the fourth quarter. BlackRock Inc. now owns 2,977,436 shares of the biotechnology company’s stock valued at $53,891,000 after acquiring an additional 91,012 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Heron Therapeutics by 11.8% in the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock valued at $29,036,000 after acquiring an additional 221,362 shares during the last quarter. Rubric Capital Management LP increased its position in shares of Heron Therapeutics by 11.8% in the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock valued at $30,685,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Balyasny Asset Management LLC increased its position in shares of Heron Therapeutics by 2.1% in the second quarter. Balyasny Asset Management LLC now owns 1,221,403 shares of the biotechnology company’s stock valued at $16,916,000 after acquiring an additional 24,688 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Leerink Swann Comments on Heron Therapeutics Inc’s FY2020 Earnings (HRTX)” was first published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US & international copyright law. The original version of this news story can be accessed at https://weekherald.com/2018/02/15/analysts-set-expectations-for-heron-therapeutics-incs-fy2020-earnings-hrtx.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply